Mesoblast (NASDAQ:MESO, ASX:MSB) received a complete response letter to its biologics license application resubmission for remestemcel-L for the treatment of pediatric steroid-refractory acute graft versus host disease...
William Blair initiated coverage of Mesoblast (NASDAQ:MESO) with an “outperform” rating and fair value estimate of $8. The stock closed at $3.03 on March 8. Mesoblast is developing mesenchymal lineage cell-derived...
Dawson James downgraded Mesoblast (NASDAQ:MESO; ASX:MSB) to “neutral” and removed its price target after the stock was halted on Aug. 4 in Australia with news of a proposed private placement and another notice of a halt...
Dawson James lowered its price target for Mesoblast (NASDAQ:MESO) to $7 from $12, but retained its “buy” rating, after the company reported encouraging data from a 565-patient trial in New York Heart Association Class...
Maxim Group upgraded Mesoblast (NASDAQ:MESO) to “buy” from “hold” with a price target of $18, citing the totality of the company’s cell therapy data, which are “quite good.” The stock closed at $8.45 on April 6...
Mesoblast (NASDAQ:MESO; ASX:MSB) reported an 83% survival in 10-of-12, or 83%, of ventilator-dependent COVID-19 patients with moderate/severe acute respiratory distress syndrome (ARDS) treated during March-April 2020...
Mesoblast (NASDAQ:MESO; ASX:MSB) received clearance from the FDA for an IND application to treat patients with acute respiratory distress syndrome (ARDS) caused by COVID-19 with intravenous infusions of its allogeneic...
The FDA accepted for priority review Mesoblast’s (NASDAQ:MESO; ASX:MSB) biologics license application filing for RYONCIL, its allogeneic cell therapy for the treatment of children with steroid-refractory acute graft...
Mesoblast (NASDAQ:MESO; ASX:MSB) submitted its completed biologics license application (BLA) to the FDA for Ryoncil, its lead allogeneic cell therapy for the treatment of children with steroid-refractory acute graft...
Mesoblast (NASDAQ:MESO; ASX:MSB) plans to file the final module of the rolling biologics license application for Ryoncil with the FDA in January and then request a priority review of the BLA under the product...